David R. Goldsmith

4.9k total citations · 2 hit papers
52 papers, 3.5k citations indexed

About

David R. Goldsmith is a scholar working on Biological Psychiatry, Psychiatry and Mental health and Behavioral Neuroscience. According to data from OpenAlex, David R. Goldsmith has authored 52 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Biological Psychiatry, 27 papers in Psychiatry and Mental health and 22 papers in Behavioral Neuroscience. Recurrent topics in David R. Goldsmith's work include Tryptophan and brain disorders (33 papers), Stress Responses and Cortisol (22 papers) and Schizophrenia research and treatment (21 papers). David R. Goldsmith is often cited by papers focused on Tryptophan and brain disorders (33 papers), Stress Responses and Cortisol (22 papers) and Schizophrenia research and treatment (21 papers). David R. Goldsmith collaborates with scholars based in United States, Canada and United Kingdom. David R. Goldsmith's co-authors include Brian J. Miller, Mark Hyman Rapaport, Jennifer C. Felger, Ebrahim Haroon, Andrew H. Miller, Bobbi J. Woolwine, Evanthia C. Wommack, Andrea L. Glenn, James K. Rilling and Giuseppe Pagnoni and has published in prestigious journals such as SHILAP Revista de lepidopterología, NeuroImage and Biological Psychiatry.

In The Last Decade

David R. Goldsmith

49 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression

2016 1.2k citations David R. Goldsmith, Mark Hyman Rapaport et al. Molecular Psychiatry profile →
Inflammation-Related Functional and Structural Dysconnectivity as a Pathway to Psychopathology

2022 132 citations David R. Goldsmith, Mandakh Bekhbat et al. profile →

Peers

David R. Goldsmith

PMH

NEURO

Stefania Bonaccorso United Kingdom

Susanne Lucae Germany

Bobbi J. Woolwine United States

Katherine E. Tansey United Kingdom

Toshiya Teraishi Japan

Sandra Dehning Germany

Dorota Frydecka Poland

Teruhiko Higuchi Japan

Amirhossein Modabbernia Iran

Giulia Perini Italy

Stefania Bonaccorso United Kingdom

David R. Goldsmith

1.1k ×0.5

768 ×0.6

1.1k ×1.1

PMH

281 ×0.6

NEURO

502 ×1.1

Citations per year, relative to David R. Goldsmith David R. Goldsmith (= 1×) peers Stefania Bonaccorso

Countries citing papers authored by David R. Goldsmith

Since Specialization

Citations

This map shows the geographic impact of David R. Goldsmith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David R. Goldsmith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David R. Goldsmith more than expected).

Fields of papers citing papers by David R. Goldsmith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David R. Goldsmith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David R. Goldsmith. The network helps show where David R. Goldsmith may publish in the future.

Co-authorship network of co-authors of David R. Goldsmith

This figure shows the co-authorship network connecting the top 25 collaborators of David R. Goldsmith. A scholar is included among the top collaborators of David R. Goldsmith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David R. Goldsmith. David R. Goldsmith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goldsmith, David R., Gregory P. Strauss, Robin Gross, et al.. (2025). Inflammation is associated with avolition and reduced resting state functional connectivity in corticostriatal reward circuitry in patients with schizophrenia. Neuropsychopharmacology. 50(11). 1706–1714. 2 indexed citations

Bekhbat, Mandakh, David R. Goldsmith, Ngoc‐Anh Le, et al.. (2025). Lipids and C-reactive protein predict anhedonia and reward circuit functional connectivity responses to anti-cytokine and dopaminergic therapies in patients with depression. Comprehensive Psychoneuroendocrinology. 21. 100284–100284. 3 indexed citations

Cohen, Simon, David R. Goldsmith, Jean Addington, et al.. (2024). Sleep disturbance, suicidal ideation and psychosis-risk symptoms in individuals at clinical high risk for psychosis. Psychiatry Research. 341. 116147–116147. 6 indexed citations

Chandra, Anjali, Brian J. Miller, & David R. Goldsmith. (2023). Predictors of successful anti-inflammatory drug trials in patients with schizophrenia: A meta-regression and critical commentary. Brain Behavior and Immunity. 114. 154–162. 5 indexed citations

Rootes-Murdy, Kelly, David R. Goldsmith, & Jessica A. Turner. (2022). Clinical and Structural Differences in Delusions Across Diagnoses: A Systematic Review. Frontiers in Integrative Neuroscience. 15. 726321–726321. 10 indexed citations

Goldsmith, David R., et al.. (2021). The interaction of lipids and inflammatory markers predict negative symptom severity in patients with schizophrenia. Schizophrenia. 7(1). 50–50. 10 indexed citations

Bekhbat, Mandakh, David R. Goldsmith, Bobbi J. Woolwine, et al.. (2021). Transcriptomic signatures of psychomotor slowing in peripheral blood of depressed patients: evidence for immunometabolic reprogramming. Molecular Psychiatry. 26(12). 7384–7392. 20 indexed citations

Lucido, Michael J., Mandakh Bekhbat, David R. Goldsmith, et al.. (2021). Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications. Pharmacological Reviews. 73(3). 1084–1117. 67 indexed citations

Cotes, Robert O., et al.. (2021). A Comparison of Attitudes, Comfort, and Knowledge of Clozapine Among Two Diverse Samples of US Psychiatrists. Community Mental Health Journal. 58(3). 517–525. 12 indexed citations

10.

Goldsmith, David R. & Mark Hyman Rapaport. (2020). Inflammation and Negative Symptoms of Schizophrenia: Implications for Reward Processing and Motivational Deficits. Frontiers in Psychiatry. 11. 46–46. 69 indexed citations

11.

Pearce, Bradley D., David R. Goldsmith, Alaaeddin Alrohaibani, et al.. (2020). Toxoplasma gondii Effects on the Relationship of Kynurenine Pathway Metabolites to Acoustic Startle Latency in Schizophrenia vs. Control Subjects. Frontiers in Psychiatry. 11. 552743–552743. 5 indexed citations

12.

Goldsmith, David R., Bradley D. Pearce, Evanthia C. Wommack, et al.. (2020). Inflammatory markers are associated with psychomotor slowing in patients with schizophrenia compared to healthy controls. Schizophrenia. 6(1). 8–8. 20 indexed citations

13.

Goldsmith, David R., Ebrahim Haroon, Andrew H. Miller, et al.. (2018). Association of baseline inflammatory markers and the development of negative symptoms in individuals at clinical high risk for psychosis. Brain Behavior and Immunity. 76. 268–274. 55 indexed citations

14.

Goldsmith, David R., Ebrahim Haroon, Andrew H. Miller, et al.. (2018). TNF-α and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia. Schizophrenia Research. 199. 281–284. 100 indexed citations

15.

Haroon, Ebrahim, Bobbi J. Woolwine, David R. Goldsmith, et al.. (2018). Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder. Psychoneuroendocrinology. 95. 43–49. 215 indexed citations

16.

Cotes, Robert O., David R. Goldsmith, Sarah L. Kopelovich, Cathy Lally, & Benjamin G. Druss. (2017). Characteristics of Medicaid Recipients Receiving Persistent Antipsychotic Polypharmacy. Community Mental Health Journal. 54(6). 699–706. 9 indexed citations

17.

Goldsmith, David R. & Robert O. Cotes. (2017). An Unmet Need. The Primary Care Companion For CNS Disorders. 19(4). 5 indexed citations

18.

Goldsmith, David R., Ebrahim Haroon, Bobbi J. Woolwine, et al.. (2016). Inflammatory markers are associated with decreased psychomotor speed in patients with major depressive disorder. Brain Behavior and Immunity. 56. 281–288. 102 indexed citations

19.

Miller, Brian J., et al.. (2016). Parental type 2 diabetes in patients with non-affective psychosis. Schizophrenia Research. 175(1-3). 223–225. 8 indexed citations

20.

Goldsmith, David R. & Keri Wellington. (2005). Naftidrofuryl. Drugs & Aging. 22(11). 967–977. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact